Announced
Completed
Synopsis
Sanofi, a French multinational pharmaceutical company, completed the $30m investment in MeiraGTx, a vertically integrated, clinical-stage gene therapy company. “We are very pleased with this first strategic investment from Sanofi. We view Sanofi’s interest in our Riboswitch gene regulation technology and our clinical Xerostomia program as further validation of the broad potential of our vertically integrated platform and we are excited to work with Sanofi as we advance these programs,” Alexandria Forbes, MeiraGTx President and CEO.
Principals
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.